In accordance with Section 3 of the Articles of Association of Orion Corporation, 823,000 A-shares have been converted into 823,000 B-shares. The conversion has been entered into the Trade Register on 19 November 2012.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 43,470,218 A-shares and 97,787,610 B-shares.
Olli Huotari Jari Karlson
Senior VP, Corporate Functions CFO
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.